There are 2789 resources available
254P - Impact of palbociclib-dose reduction on survival: A retrospective cohort study
Presenter: Maria Luisa Romero Lagures
Session: ePoster Display
255P - Propreseer: A reliable, collaborative prognostic model for tamoxifen-resistance breast cancer
Presenter: Weiqi Nian
Session: ePoster Display
Resources:
Abstract
256P - PI3K mutation is associated with reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer
Presenter: Keechilat Pavithran
Session: ePoster Display
257P - Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
Presenter: Sibylle Loibl
Session: ePoster Display
309P - Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) + fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (Mut) advanced breast cancer (ABC): An analysis from SOLAR-1
Presenter: Fabrice André
Session: ePoster Display
259P - Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer
Presenter: Michaela Tsai
Session: ePoster Display
260P - High enrichment of ATRX mutations in lung and liver metastasis of breast cancer
Presenter: Rongrong Chen
Session: ePoster Display
262P - Pattern of failure and treatment results in triple-negative breast cancer patients
Presenter: Sherif Farouk El Zawawy
Session: ePoster Display
263P - Predicting bevacizumab efficacy in mTNBC
Presenter: Heba Bakri
Session: ePoster Display